Page last updated: 2024-10-25

ciprofloxacin and Acantholysis Bullosa

ciprofloxacin has been researched along with Acantholysis Bullosa in 1 studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Research Excerpts

ExcerptRelevanceReference
"Ciprofloxacin-resistant SA was found significantly predominant in chronic wounds (**P < ."1.91Longitudinal study of wound healing status and bacterial colonisation of Staphylococcus aureus and Corynebacterium diphtheriae in epidermolysis bullosa patients. ( Acevedo, F; Arancibia, E; Fuentes, I; Morandé, P; Oróstica, K; Palisson, F; Porte, L; Rebolledo-Jaramillo, B; Varela, C; Yubero, MJ, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Fuentes, I1
Yubero, MJ1
Morandé, P1
Varela, C1
Oróstica, K1
Acevedo, F1
Rebolledo-Jaramillo, B1
Arancibia, E1
Porte, L1
Palisson, F1

Other Studies

1 other study available for ciprofloxacin and Acantholysis Bullosa

ArticleYear
Longitudinal study of wound healing status and bacterial colonisation of Staphylococcus aureus and Corynebacterium diphtheriae in epidermolysis bullosa patients.
    International wound journal, 2023, Volume: 20, Issue:3

    Topics: Ciprofloxacin; Corynebacterium diphtheriae; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica

2023